Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up – Should You Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF)’s stock price gapped up prior to trading on Wednesday. The stock had previously closed at $42.80, but opened at $46.00. Swedish Orphan Biovitrum shares last traded at $46.00, with a volume of 102 shares changing hands.

Analysts Set New Price Targets

BIOVF has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, July 21st. Pareto Securities cut Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Finally, Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Swedish Orphan Biovitrum has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Up 7.5%

The company has a market capitalization of $16.38 billion, a PE ratio of 102.22 and a beta of 0.47. The firm’s 50-day simple moving average is $46.45 and its 200 day simple moving average is $46.37. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.